3:29 PM
 | 
Nov 07, 2018
 |  BC Extra  |  Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

Shares of at least three companies moved double digits on Wednesday after the companies provided 3Q18 financial results, with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) sliding after reporting sales for newly launched amyloidosis drug Onpattro patisiran and discontinuation of a Phase II program for atypical hemolytic uremic syndrome (aHUS).

Alnylam lost $10.23 (12%) to $76.05 following the report, representing a market cap loss of just over $1 billion. Meanwhile, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was down $24 (15%) to $140.41 after reporting weaker than expected sales, while diagnostic company Genomic Health Inc. (NASDAQ:GHDX) touched an all-time intraday high of $92.18 after reporting its numbers.

Alnylam said Onpattro...

Read the full 496 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD